• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

Dexcom launches NIL program for college athletes with diabetes

October 24, 2022 By Sean Whooley

Dexcom U Roster
[Image from Dexcom]
Dexcom (Nasdaq:DXCM) announced today that it launched Dexcom U, an NIL (name, image, likeness) program for college athletes.

The San Diego-based company aims for the program to celebrate college athletes with diabetes. The company labeled it the first-ever NIL program designed to do so.

Dexcom also hopes it inspires those with diabetes to pursue athletic dreams of their own.

The company shared data highlighting the toll of diabetes on budding athletic talent. According to a news release, nearly half (43%) of adults with type 1 diabetes felt like quitting sports and physical activities because of their diagnosis. One in five (20%) followed through with quitting.

Partnering with ESPN insider

The company partnered with ESPN Senior NFL Insider and diabetes advocate Adam Schefter. Schefter’s wife, Sharri, lives with type 1 diabetes. The program offers 14 competitors a platform to share their story and receive mentorship and support.

“For many, having diabetes used to mean giving up on your hopes and dreams,” said Schefter. “I’ve had a front-row seat to diabetes since my wife Sharri was diagnosed in 2002, and I see the hurdles that people with diabetes overcome daily, but also how the advances in diabetes care, like Dexcom CGM, have unlocked a world of possibilities for her and many others.”

The athletes also rely on their Dexcom CGM to track glucose levels in real-time, helping to manage their diabetes.

Dexcom intends to share free educational resources for parents, teachers, coaches and fellow athletes as well. These resources help break down misconceptions about diabetes, the company said.

“Dexcom has always celebrated people with diabetes who push the limits and make a positive impact on their communities, which is why we saw the Supreme Court’s NIL decision as an opportunity to elevate these outstanding young athletes,” said Anne Santoro, VP, global customer experience at Dexcom. “The creation of Dexcom U is a testament to how our Warriors are breaking barriers and leading the way as role models for others with diabetes.”

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Patient Monitoring, Technology Tagged With: Dexcom

IN CASE YOU MISSED IT

  • Dexcom CFO to expand into COO role
  • Beta Bionics insulin patch pump scores FDA clearance
  • Medtronic moves to divest final stake in MiniMed
  • Dexcom adds former Stryker CFO to board
  • MiniMed wins CE mark for next-gen insulin pump, ups revenue guidance

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS